⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 26, 2024Expert Review of Clinical Pharmacology

Population pharmacokinetics of nirmatrelvir/ritonavir in critically ill Chinese COVID-19 patients and recommendations for medication use: a two-center retrospective study

Junjun Xu Jinmeng Li Meng Chen Huifang Jiang Xudong Fan Yangmin Hu Haili Shan Mingdong Yang Yichao Xu Yuying Lang Haibin Dai Xinjun Cai

View at Publisher

Ask AI

Bookmark

Share

Abstract

This study aimed to establish population pharmacokinetics (PPK) models of nirmatrelvir/ritonavir in critically ill Chinese patients with the coronavirus disease 2019 (COVID-19) infection, explore factors affecting the pharmacokinetics (PK) of nirmatrelvir/ritonavir.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Xu et al. (2024) studied this question.

synapsesocial.com/papers/68e57542b6db643587515adc https://doi.org/10.1080/17512433.2024.2410385

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Physiologically‐based pharmacokinetic modelling guided dose evaluations of nirmatrelvir/ritonavir in renal impairment for the management of COVID‐192024 · 2 citations
2Population pharmacokinetics and pharmacodynamics of nirmatrelvir in Chinese patients with COVID‐192024 · 3 citations
3Associations of nirmatrelvir-ritonavir treatment with death and clinical improvement in hospitalized patients with COVID-19 during the Omicron wave in Beijing, China: a multicentre, retrospective cohort study2024 · 6 citations
4Pharmacokinetics of Nirmatrelvir/Ritonavir after Multiple Administration in a Phase 1, Open-Label Study in Healthy Chinese Adults and Compared with Non-Chinese Participantsother · 2026
5Safety, efficacy, and pharmacokinetics of nirmatrelvir and ritonavir in patients with severe COVID-19 and renal impairment: A case report2024

Nirmatrelvir/ritonavir reduced mortality in severe or critical COVID-19 patients: a multicenter retrospective cohort study2026
Safety, Pharmacokinetics, and Dose Recommendations for Nirmatrelvir/Ritonavir in Individuals with Mild to Moderate <scp>COVID</scp> ‐19 and Severe Renal Impairment2026
Efficacy and Safety of Nirmatrelvir/Ritonavir in Severe Hospitalized Patients with COVID-19 and in Patients at High Risk for Progression to Critical Illness: A Real-World Study2024
Pediatric medicines: a brief overview with a focus on drug reformulation and repositioningExpert Review of Clinical Pharmacology · 2026
Therapeutic utility of clinical & laboratory markers in chronic spontaneous urticaria – a narrative reviewExpert Review of Clinical Pharmacology · 2026

More from Expert Review of Clinical Pharmacology

More from Second Affiliated Hospital of Zhejiang University

More from Zhejiang Hospital

More from Hangzhou Red Cross Hospital